Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C

Detalhes bibliográficos
Autor(a) principal: Paraná, Raymundo
Data de Publicação: 2006
Outros Autores: Schinoni, Maria Isabel, Freitas, Luiz A. R. de., Codes, Liana, Cruz, Marla, Andrade, Zilton de Araújo, Trepo, Christian
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/6361
Resumo: RESTRITO
id UFBA-2_f6fff2dfe38e14f69bd69d19abd005ef
oai_identifier_str oai:repositorio.ufba.br:ri/6361
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Paraná, RaymundoSchinoni, Maria IsabelFreitas, Luiz A. R. de.Codes, LianaCruz, MarlaAndrade, Zilton de AraújoTrepo, ChristianParaná, RaymundoSchinoni, Maria IsabelFreitas, Luiz A. R. de.Codes, LianaCruz, MarlaAndrade, Zilton de AraújoTrepo, Christian2012-07-06T14:36:03Z2012-07-06T14:36:03Z20061478-3223http://www.repositorio.ufba.br/ri/handle/ri/6361v.22, n.9RESTRITOAbstract: Background/Aim: Pegylated interferon (Peg-IFN) plus ribavirin is the standard therapy for hepatitis C. Peg-IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Both drugs are associated with adverse reactions of different magnitudes. Autoimmune phenomena have been reported with this treatment. In this paper, we describe cases of ALT/GGT flares during Peg-IFN plus ribavirin treatment, which related to the appearance of anti-Golgi antibody and disease progress. Methods: We investigated three patients with hepatitis C and severe ALT/GGT flares during Peg-IFN and ribavirin treatment coinciding with anti-Golgi complex antibody as the only marker of autoimmunity. We then reviewed the medical files and tested anti-Golgi antibody in stored sera from 25 patients treated with conventional IFN and in 14 patients treated with Peg-IFN. Results: The three patients were male, over 45 years of age; all were relapsers and non-responders. Anti-Golgi antibody was positive during treatment coinciding with ALT/GGT flares but with hepatitis C virus (HCV)-RNA negativity, disappearing after stopping treatment, with normalization of ALT/AST levels. One patient had progression of fibrosis from F2 to F3 despite negativity of HCV-RNA. In the last group, only two patients treated with Peg-IFN experienced ALT/GGT flares but without anti-Golgi antibody Conclusions: The presence of anti-Golgi complex antibody could be a marker of a temporary autoimmune phenomenon and progressive disease. Infection with hepatitis C virus (HCV) is an important public health problem worldwide (1). About 55–86% of HCV patients develop chronic infection (2–4). Chronic HCV is usually characterized by a lack of symptoms or only fatigue or abdominal pain. Extra hepatic manifestations are well known and primarily associated with autoimmune or lymphoproliferative states such as arthritis, autoimmune thyroiditis, diabetes mellitus, idiopathic thrombocytopenic purpura, myasthenia gravis, Sjogren syndrome, aplastic anemia, essential mixed (type II) cryoglobulinemia, monoclonal gammopathy and non-Hodking lymphoma. Dermatological manifestations include erythema multiforme, erythema nodosun, Lichen Planus, Porphyria cutanea tarda, psoriasis, pruritus and vasculitis. Idiopathic pulmonary fibrosis and membranoproliferative glomerulonephritis have also been reported (5). Patients with chronic HCV infection do have a higher prevalence rate of autoantibodies in the serum (6). The determination of the antinuclear antibody has thus been recommended before starting HCV therapy (7). Since 1999, interferon (IFN) plus ribavirin is considered as the standard of care for hepatitis C (8). IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect (9). Despite its broad spectrum of antiviral activity, ribavirin has a negligible direct antiviral action against HCV replication when used in monotherapy. In contrast, it potentiates IFN activity when added to it, suggesting an additional immunomodulatory effect (10). Both drugs are related to adverse reactions of different magnitudes. Among these side-effects, anemia, neutropenia, thrombopenia, depression and fatigue are the most common, but less frequent adverse reactions related to autoimmune phenomena have been frequently reported. Therapy with IFN-α does also induce autoantibodies in more than half of the patients treated for chronic hepatitis C. Common antibodies are antithyroid, antinuclear antibodies and antibodies against insulin. In the majority of these patients, no evidence of autoimmune disease will develop. However, in susceptible patients, autoimmune features may occur (11, 12). Another unusual side-effect is autoimmune hepatitis, which can prompt immediate discontinuation of the treatment (13). Antithyroid antibodies and autoimmune thyroiditis seem to be the most common side-effects attributable to the immunomodulatory role of IFN. Autoimmune hemolytic anemia and immune-mediated thrombocytopenia purpura were related to this therapy. Autoimmune arthritis including rheumatoid arthritis can emerge during IFN-α therapy as well as systemic lupus erythematosus-like syndrome. Diabetes mellitus may worsen or develop during this therapy (11–16). More recently, Pegylated interferon (Peg-IFN) replaced the conventional one because of best results in terms of sustained virological response (17, 18). Although these newer agents are significantly more effective than earlier versions of standard IFN, the side-effect profile of IFN-based therapies has remained unchanged despite increased incidence of AES. Thus, influenza-like symptoms (fever, myalgia and rigor) and several gastrointestinal disturbances occur with increased frequency (P<0.05) in those treated with Peg-IFN combination therapy compared with standard IFN and ribavirine (19–21). New side-effects of this therapy are reported continuously with the acknowledgment of the results of the different trials (22). During Peg-IFN plus ribavirin treatment, some ALT and GGT elevations are observed, but its mechanism remains unknown (18). Such liver enzyme elevations do not seem to alter antiviral response and even mild to moderate flares are considered benign as they are not related to liver disease progression. In this paper, we described cases of ALT/GGT flares during Peg-IFN plus ribavirin treatment, which were related to anti-Golgi antibody appearance and progressive liver disease. Interestingly, the Golgi apparatus may serve as the starting site of morphological changes associated with viral infection and replication leading to cell fusion and syncytia formation.Submitted by Santiago Fabio (fabio.ssantiago@hotmail.com) on 2012-07-06T14:36:03Z No. of bitstreams: 1 BB.pdf: 597871 bytes, checksum: caa0974b7b405828343650aa19017da3 (MD5)Made available in DSpace on 2012-07-06T14:36:03Z (GMT). No. of bitstreams: 1 BB.pdf: 597871 bytes, checksum: caa0974b7b405828343650aa19017da3 (MD5) Previous issue date: 2006Liver InternationalDOI: 10.1111/j.1478-3231.2006.01345.xreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAAnti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis CLiver Internationalinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleenginfo:eu-repo/semantics/openAccessORIGINALBB.pdfBB.pdfapplication/pdf597871https://repositorio.ufba.br/bitstream/ri/6361/1/BB.pdfcaa0974b7b405828343650aa19017da3MD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/6361/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXTBB.pdf.txtBB.pdf.txtExtracted texttext/plain25333https://repositorio.ufba.br/bitstream/ri/6361/3/BB.pdf.txt9659c1690cbd5415ecac890a803c2de4MD53ri/63612022-07-05 14:03:29.952oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:29Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
dc.title.alternative.pt_BR.fl_str_mv Liver International
title Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
spellingShingle Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
Paraná, Raymundo
title_short Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_full Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_fullStr Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_full_unstemmed Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
title_sort Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
author Paraná, Raymundo
author_facet Paraná, Raymundo
Schinoni, Maria Isabel
Freitas, Luiz A. R. de.
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trepo, Christian
author_role author
author2 Schinoni, Maria Isabel
Freitas, Luiz A. R. de.
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trepo, Christian
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Paraná, Raymundo
Schinoni, Maria Isabel
Freitas, Luiz A. R. de.
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trepo, Christian
Paraná, Raymundo
Schinoni, Maria Isabel
Freitas, Luiz A. R. de.
Codes, Liana
Cruz, Marla
Andrade, Zilton de Araújo
Trepo, Christian
description RESTRITO
publishDate 2006
dc.date.issued.fl_str_mv 2006
dc.date.accessioned.fl_str_mv 2012-07-06T14:36:03Z
dc.date.available.fl_str_mv 2012-07-06T14:36:03Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/6361
dc.identifier.issn.none.fl_str_mv 1478-3223
dc.identifier.number.pt_BR.fl_str_mv v.22, n.9
identifier_str_mv 1478-3223
v.22, n.9
url http://www.repositorio.ufba.br/ri/handle/ri/6361
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Liver International
publisher.none.fl_str_mv Liver International
dc.source.pt_BR.fl_str_mv DOI: 10.1111/j.1478-3231.2006.01345.x
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/6361/1/BB.pdf
https://repositorio.ufba.br/bitstream/ri/6361/2/license.txt
https://repositorio.ufba.br/bitstream/ri/6361/3/BB.pdf.txt
bitstream.checksum.fl_str_mv caa0974b7b405828343650aa19017da3
1b89a9a0548218172d7c829f87a0eab9
9659c1690cbd5415ecac890a803c2de4
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459403326652416

Registros relacionados